Viatris' EBITDA 2018-2023
In 2023, Viatris reported an EBITDA of around 3.5 billion U.S. dollars, a decrease compared to the previous year at around two billion U.S. dollars. This statistic shows the earnings before interest, taxes, depreciation and amortization (EBITDA) of pharmaceutical company Viatris from 2018 to 2023.
Viatris is a global healthcare company headquartered in the United States with global centers in Pennsylvania, Shanghai and Hyderabad, India. The company was formed in November 2020 through the combination of Mylan and the Upjohn Business (owned by Pfizer Inc.). Its global portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized iconic brands (such as Viagra, Xanax, Lipitor).
Viatris is a global healthcare company headquartered in the United States with global centers in Pennsylvania, Shanghai and Hyderabad, India. The company was formed in November 2020 through the combination of Mylan and the Upjohn Business (owned by Pfizer Inc.). Its global portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized iconic brands (such as Viagra, Xanax, Lipitor).
